

Document and entity information

	Dec 2024	Jun 2024
Company information		
Company information		
FASF member mark		true
Document name		第2四半期（中間期） 決算短信〔日本基準〕（連結）
Filing date		2024-08-09
Company name		TAIKO PHARMACEUTICAL CO.,LTD.
Stock exchange listings		
Tokyo		true
Tokyo Prime		true
Tokyo Standard		-
Tokyo Growth		-
Tokyo PRO Market		-
Tokyo Others		-
Nagoya		-
Nagoya Premire		-
Nagoya Main		-
Nagoya Next		-
Nagoya Others		-
Sapporo		-
Sapporo		-
Sapporo Ambitious		-
Sapporo Others		-
Fukuoka		-
Fukuoka		-
Fukuoka Q-Board		-
Fukuoka Others		-
Phoenix		-
Japan Securities Dealers Association		-
Securities code		45740
URL		https://www.seirogan.co.jp
Business category		
General Business	true	
Specific Business	-	
Fiscal Year End	2024-12-31	
Quarterly period		2
Representative		
Title		代表取締役社長
Name		柴田 高
Inquiries		
Title		コーポレート本部 経 理部長
Name		中條 亨
Tel		-
Other		
Semi-annual statement filing date (as planned)		2024-08-09
Supplemental material of results		true
Way of getting		-
Convening briefing of results		true
Target for briefing of results		（機関投資家・アナ リスト向け）
Note to fraction processing method		（百万円未満切捨 て）

Business Results-Quarterly operating results

(in millions of yens)

	Jun 2024	Jun 2023
Quarterly operating results		
Quarterly operating results		
Consolidated operating results		
Consolidated income statements information		
Net sales		
Net sales	2,860	2,488
% change	14.9	34.0
Operating profit		
Operating profit	482	-396
% change	-	-
Ordinary profit		
Ordinary profit	528	-510
% change	-	-
Profit attributable to owners of parent		
Profit attributable to owners of parent	764	-514
% change	-	-
Note to consolidated income statements information		
Comprehensive income		
Comprehensive income	1,257	-334
Change in comprehensive income	-	-
Other consolidated operating results		
Basic earnings per share (Yen)	15.24	-11.36
Diluted earnings per share (Yen)	-	-
Note to consolidated operating results		
Note to operating results	<p>(注) 1. 2023年12月期中間期の潜在株式調整後1株当たり中間純利益については、希薄化効果を有している潜在株式が存在するものの1株当たり中間純損失であるため記載しておりません。2. 2024年12月期中間期の潜在株式調整後1株当たり中間純利益については、潜在株式が存在しないため記載しておりません。</p>	

Business Results-Quarterly financial positions

(in millions of yens)

	Jun 2024	Dec 2023
Quarterly financial positions		
Quarterly financial positions		
Consolidated financial positions		
Total assets	13,383	13,220
Net assets	8,074	6,739
Capital adequacy ratio (%)	60.3	51.0
Note to consolidated financial positions		
Owner's equity	8,074	6,739
Note to financial positions	-	-

Business Results-Note to quarterly business results

	Jun 2024
Quarterly note to business results	
Quarterly note to business results	
Note to consolidated financial results	
Note to consolidated financial results	-

Quarterly Dividends

(in millions of yens)

	Dec 2024	Jun 2024	Dec 2023
Quarterly dividends			
Quarterly dividends			
Dividends			
Dividend per share (Yen)			
Dividend per share (Yen)			
First quarter			
Result	-		-
Second quarter			
Result	0.00		0.00
Third quarter			
Result			-
Forecast	-		
Upper	-		
Lower	-		
Year end			
Result			0.00
Forecast	-		
Upper	-		
Lower	-		
Annual			
Result			0.00
Forecast	-		
Upper	-		
Lower	-		
Correction of dividend forecast from the most recent dividend forecast			
Correction of dividend forecast from the most recent dividend forecast			
Annual	-		
Note to dividends			
Note to dividends			
Annual			

(注) 2024年12月期の配当予想につきましては、現時点では「未定」といたします。

Quarterly Forecasts

(in millions of yens)

	Dec 2024
Quarterly forecasts	
Quarterly forecasts	
Title for forecasts	3. 2024年12月期の連結業績予想(2024年1月1日~2024年12月31日)
Preamble to consolidated forecasts	
Preamble to forecasts	-
Main table of consolidated forecasts	
Net sales	
Net sales	
Forecast	6,800
Upper	-
Lower	-
% change	
Forecast	11.1
Upper	-
Lower	-
Operating profit	

Operating profit	
Forecast	550
Upper	-
Lower	-
% change	
Forecast	-
Upper	-
Lower	-
Ordinary profit	
Ordinary profit	
Forecast	590
Upper	-
Lower	-
% change	
Forecast	-
Upper	-
Lower	-
Profit attributable to owners of parent	
Profit attributable to owners of parent	
Forecast	550
Upper	-
Lower	-
% change	
Forecast	-
Upper	-
Lower	-
Basic earnings per share (Yen)	
Basic earnings per share (Yen)	
Forecast	10.97
Upper	-
Lower	-
Note to consolidated forecasts	
Note to forecasts	(注)連結業績予想の修正につきましては、本日(2024年8月9日)公表いたしました「連結業績予想の修正及び医薬品事業における生産体制の再編(減損損失の計上)に関するお知らせ」をご覧ください。
Correction of financial forecast from the most recent financial forecast	
Correction of financial forecast from the most recent financial forecast	
Forecast	true

Notes-Significant changes in the scope of consolidation during the period

(in millions of yens)

Jun 2024

Significant changes in the scope of consolidation during the period	
Significant changes in the scope of consolidation during the period	
Others	
Significant changes in the scope of consolidation during the period	
Significant changes in the scope of consolidation during the period	-
Note to significant changes in the scope of consolidation during the period	
Note to significant changes in the scope of consolidation during the period	-

Notes, Semiannual-Applying of specific accounting of the consolidated semi-annual financial statements

Jun 2024

Applying of specific accounting of the consolidated semi-annual financial statements

Applying of specific accounting of the consolidated semi-annual financial statements

Others

Applying of specific accounting of the consolidated semi-annual financial statements

Applying of specific accounting of the consolidated semi-annual financial statements

-

Note to applying of specific accounting of the consolidated semi-annual financial statements

Note to applying of specific accounting of the consolidated semi-annual financial statements

-

Notes, Quarterly-Changes in accounting policies and accounting estimates retrospective restatement

Jun 2024

Changes in accounting policies, accounting estimates and retrospective restatement

Changes in accounting policies, accounting estimates and retrospective restatement

Others

Changes in accounting policies, accounting estimates and retrospective restatement

Changes in accounting policies based on revisions of accounting standard

-

Changes in accounting policies other than ones based on revisions of accounting standard

-

Changes in accounting estimates

-

Retrospective restatement

-

Note to changes in accounting policies, accounting estimates and retrospective restatement

Note to changes in accounting policies, accounting estimates and retrospective restatement

-

Notes, Quarterly-Number of issued and outstanding shares common stock

Jun 2024

Dec 2023

Jun 2023

Number of issued and outstanding shares (common stock)

Number of issued and outstanding shares (common stock)

Others

Number of issued and outstanding shares (common stock)

Number of issued and outstanding shares at the end of fiscal year (including treasury stock)

50,636,900

50,436,900

Number of treasury stock at the end of fiscal year

443,189

487,124

Average number of shares

50,171,896

45,321,409

Note to number of issued and outstanding shares (common stock)

Note to number of issued and outstanding shares (common stock)

-

This information is a summary of the earnings report. It does not contain all details included in the earnings report disclosed in Japanese.